Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Oct;259(7):413-31.
doi: 10.1007/s00406-009-0024-2. Epub 2009 Jul 16.

Cannabis and psychosis/schizophrenia: human studies

Deepak Cyril D'Souza  1 , Richard Andrew Sewell, Mohini Ranganathan
Affiliations
Review

Cannabis and psychosis/schizophrenia: human studies

Deepak Cyril D'Souza et al. Eur Arch Psychiatry Clin Neurosci. 2009 Oct.

Abstract

The association between cannabis use and psychosis has long been recognized. Recent advances in knowledge about cannabinoid receptor function have renewed interest in this association. Converging lines of evidence suggest that cannabinoids can produce a full range of transient schizophrenia-like positive, negative, and cognitive symptoms in some healthy individuals. Also clear is that in individuals with an established psychotic disorder, cannabinoids can exacerbate symptoms, trigger relapse, and have negative consequences on the course of the illness. The mechanisms by which cannabinoids produce transient psychotic symptoms, while unclear may involve dopamine, GABA, and glutamate neurotransmission. However, only a very small proportion of the general population exposed to cannabinoids develop a psychotic illness. It is likely that cannabis exposure is a "component cause" that interacts with other factors to "cause" schizophrenia or a psychotic disorder, but is neither necessary nor sufficient to do so alone. Nevertheless, in the absence of known causes of schizophrenia, the role of component causes remains important and warrants further study. Dose, duration of exposure, and the age of first exposure to cannabinoids may be important factors, and genetic factors that interact with cannabinoid exposure to moderate or amplify the risk of a psychotic disorder are beginning to be elucidated. The mechanisms by which exposure to cannabinoids increase the risk for developing a psychotic disorder are unknown. However, novel hypotheses including the role of cannabinoids on neurodevelopmental processes relevant to psychotic disorders are being studied.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Δ9-THC induces transient psychotomimetic effects in healthy individuals. Effects of Δ9-THC on the seven-item positive symptom subscale of the Positive and Negative Syndrome Scale (PANSS) (left panel) and the clinician rated subscale of the clinician administered dissociative symptoms scale (CADSS) (right panel). The PANSS is used to measure the symptoms associated with schizophrenia. Scores for each item range from 0 (absent) to 7 (extremely). The range of scores on the PANSS positive subscale is 0–49. The CADSS is used to measure perceptual alterations. Scores for each item range from 0 (absent) to 4 (extremely). The range of scores on the CADSS clinician-rated subscale is 0–32. Green circles placebo (vehicle); blue squares 2.5 mg Δ9-THC; red triangle 5 mg Δ9-THC
Fig. 2
Fig. 2
Δ9-THC induces memory impairments. Effects of Δ9-THC on learning, immediate free recall, delayed free recall, delayed cued and recognition recall measured by a 12-word learning task (Hopkins verbal learning test). Green circles placebo (vehicle); blue squares 2.5 mg Δ9-THC; red triangle 5 mg Δ9-THC; solid line schizophrenia; dotted line controls
Fig. 3
Fig. 3
Enhanced sensitivity to the psychotomimetic effects of Δ9-THC in schizophrenia. Peak increase in positive symptoms measured by the positive symptoms subscale of the positive and negative symptoms scale (PANSS) (group means 1 SD). Clinically significant increase = 3 point or greater increase in PANSS positive symptom subscale score. Yellow symbols placebo; green symbols 2.5 mg Δ9-THC; red symbols 5 mg Δ9-THC; circles control; triangle schizophrenia
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data bring new evidence. Int J Neuropsychopharmacol. 2004;7(Suppl 1):S1–S5. - PubMed
    1. Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y, Hwang DR, Keilp J, Kochan L, Van Heertum R, Gorman JM, Laruelle M. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci. 2002;22:3708–3719. - PMC - PubMed
    1. Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. Addiction. 1999;91:1585–1614. - PubMed
    1. Addington J, Addington D. Effect of substance misuse in early psychosis. Br J Psychiatry Suppl. 1998;172:134–136. - PubMed
    1. Addington J, Duchak V. Reasons for substance use in schizophrenia. Acta Psychiatr Scand. 1997;96:329–333. - PubMed

Substances

-